ECSP15002095A - Formulación farmacéutica - Google Patents

Formulación farmacéutica

Info

Publication number
ECSP15002095A
ECSP15002095A ECIEPI20152095A ECPI201502095A ECSP15002095A EC SP15002095 A ECSP15002095 A EC SP15002095A EC IEPI20152095 A ECIEPI20152095 A EC IEPI20152095A EC PI201502095 A ECPI201502095 A EC PI201502095A EC SP15002095 A ECSP15002095 A EC SP15002095A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulation
high concentration
antibody
present
viscosity
Prior art date
Application number
ECIEPI20152095A
Other languages
English (en)
Inventor
Andrew Jeffrey Yates
James Gregory Clipstone
Original Assignee
Dolivar Coraucci Neto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP15002095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dolivar Coraucci Neto filed Critical Dolivar Coraucci Neto
Publication of ECSP15002095A publication Critical patent/ECSP15002095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a métodos y medios para reducir la viscosidad de una formulación farmacéutica que comprende un anticuerpo u otra proteína terapéutica a una elevada concentración. La presente invención proporciona una formulación farmacéutica líquida que comprende un anticuerpo a concentración elevada con una viscosidad reducida que no impide su procesamiento ni la inyección de la formulación farmacéutica.
ECIEPI20152095A 2012-06-21 2015-01-21 Formulación farmacéutica ECSP15002095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21

Publications (1)

Publication Number Publication Date
ECSP15002095A true ECSP15002095A (es) 2015-11-30

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20152095A ECSP15002095A (es) 2012-06-21 2015-01-21 Formulación farmacéutica

Country Status (25)

Country Link
US (1) US20150150979A1 (es)
EP (1) EP2864356A1 (es)
JP (1) JP6157611B2 (es)
KR (1) KR20150032941A (es)
CN (1) CN104520326A (es)
AR (1) AR091530A1 (es)
AU (1) AU2013279347A1 (es)
BR (1) BR112014031841A2 (es)
CA (1) CA2876012A1 (es)
CL (1) CL2014003283A1 (es)
CO (1) CO7170174A2 (es)
EA (1) EA201590061A1 (es)
EC (1) ECSP15002095A (es)
HK (1) HK1205146A1 (es)
IL (1) IL235921A0 (es)
MA (1) MA37777B1 (es)
MX (1) MX2014014717A (es)
NZ (1) NZ702342A (es)
PE (1) PE20150190A1 (es)
PH (1) PH12014502596A1 (es)
SG (1) SG11201407779YA (es)
TN (1) TN2014000498A1 (es)
TW (1) TW201406398A (es)
WO (1) WO2013190047A1 (es)
ZA (1) ZA201409020B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． 粘度低下物質を含有する、多糖および核酸の調合薬
CA3026426C (en) * 2016-05-28 2021-04-13 Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Bio-Technology, Government Of India Uttroside b and derivatives thereof as therapeutics for hepatocellular carcinoma
EP3964197A1 (en) * 2016-10-31 2022-03-09 Fresenius Kabi Deutschland GmbH Liquid pharmaceutical composition
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN120392659A (zh) 2017-01-11 2025-08-01 赛特瑞恩股份有限公司 稳定的液体调配物
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
WO2022109052A1 (en) * 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators
CA3198795A1 (en) 2020-11-18 2022-05-27 Jeffrey Becker Complexing agent salt formulations of pharmaceutical compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
WO2006096461A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
EP2114451A2 (en) * 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
ES2707815T3 (es) * 2007-06-14 2019-04-05 Biogen Ma Inc Formulaciones de anticuerpo natalizumab
RU2012151500A (ru) * 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
CA2803998A1 (en) * 2010-07-02 2012-01-05 Medimmune, Llc Antibody formulations
BR112013025845A2 (pt) * 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
CN103501825B (zh) * 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩

Also Published As

Publication number Publication date
MA20150436A1 (fr) 2015-11-30
JP2015520206A (ja) 2015-07-16
JP6157611B2 (ja) 2017-07-05
PH12014502596A1 (en) 2015-01-12
EP2864356A1 (en) 2015-04-29
WO2013190047A1 (en) 2013-12-27
SG11201407779YA (en) 2015-02-27
MX2014014717A (es) 2015-03-06
TN2014000498A1 (en) 2016-03-30
CL2014003283A1 (es) 2016-04-01
IL235921A0 (en) 2015-01-29
EA201590061A1 (ru) 2015-05-29
ZA201409020B (en) 2016-09-28
PE20150190A1 (es) 2015-02-13
BR112014031841A2 (pt) 2017-06-27
AU2013279347A1 (en) 2014-12-18
CA2876012A1 (en) 2013-12-27
AR091530A1 (es) 2015-02-11
CO7170174A2 (es) 2015-01-28
HK1205146A1 (en) 2015-12-11
NZ702342A (en) 2016-07-29
US20150150979A1 (en) 2015-06-04
CN104520326A (zh) 2015-04-15
TW201406398A (zh) 2014-02-16
MA37777B1 (fr) 2017-07-31
KR20150032941A (ko) 2015-03-31

Similar Documents

Publication Publication Date Title
ECSP15002095A (es) Formulación farmacéutica
PH12019501931A1 (en) Anti-pdl1 antibody formulations
MX382917B (es) Formulaciones de proteínas líquidas que contienen líquidos iónicos.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX386886B (es) Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
CL2014002549A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
CL2015000352A1 (es) Métodos de tratamiento de una tauopatía
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
MX388858B (es) Reducción de la viscosidad de formulaciones farmacéuticas
BR112015006731A2 (pt) combinações e usos das mesmas
PH12016500720A1 (en) Stable formulation of insulin glulisine
UA117228C2 (uk) Фармацевтична композиція, що містить антитіло до gm-csf
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
CL2016000944A1 (es) Nueva formulación de ganadotropinas
BR112015031585A2 (pt) composição farmacêutica
UY35795A (es) Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran
UA116011C2 (uk) Частинки фенілефрину резинату та їх використання у фармацевтичних композиціях
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
AR096455A1 (es) Vacuna para la malaria
UA106905U (uk) Фармацевтична композиція
EA201592232A1 (ru) Применение денцихина в получении лекарственного средства для лечения тромбоцитопении